Section: Bilateral Contracts and Grants with Industry

Bilateral Contracts with Industry

Bilateral Contracts with Industry

Transgene 1. (2016-2017)

Participants: A. Gégout-Petit, A. Muller-Gueudin, Y. Shi

Transgene (Euronext: TNG), part of Institut Mérieux, is a publicly traded French biopharmaceutical company focused on discovering and developing targeted immunotherapies for the treatment of cancer and infectious diseases. B. Bastien, head of the biostatistics team appeals to BIGS to select covariates among genomics, proteomics expressions linked to the success of a treatment of the lung cancer. This subject was the purpose of the master thesis of Y. Shi and a paper on the subject is in preparation.

Transgene 2. (2016-2017)

Participants: T. Bastogne, L. Batista, P. Vallois

Transgene (Euronext: TNG), part of Institut Mérieux, is a publicly traded French biopharmaceutical company focused on discovering and developing targeted immunotherapies for the treatment of cancer and infectious diseases. B. Bastien, head of the biostatistics team appeals to BIGS to model data collected in vivo for growth tumor and to measure the effect of the treatment on the dynamics of the tumor.

SAFRAN Aircraft Engines (2016-2019)

Participants: R. Azaïs, A. Gégout-Petit, F. Greciet

SAFRAN Aircraft Engines designs and products Aircraft Engines. For the design of pieces, they have to understand mechanism of crack propagation under different conditions. It appeals to BIGS for modeling crack propagation with Piecewise Deterministic Markov Processes (PDMP). It is the subject of F. Greciet PhD, granted by ANRT. F. Greciet presented her work during a Fédération Charles Hermite Journey on November the 23th. She was laureat of "Mathématiques, oxygene du monde numérique" poster challenge [52].

CYBERNANO (2014-2017)

Participants: T. Bastogne, L. Batista, P. Guyot

Cybernano is a start-up founded in 2013 by one BIGS member: T. Bastogne. Cybernano develops computational services to analyze high-content data in cell biology for applications in oncology, cardiotoxicity and virology. After the end of his PhD (2017), L. Batista became chief technical officer of Cybernano. A EuroStars project proposal was submitted in Sep. 2017 in which Cybernano will be the leader and BIGS a scientific partner (Eurostars is a H2020 programme that supports research-performing small and medium enterprises).